TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04257747

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI acquisitions
Description: MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI acquisitions
Description: MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI acquisitions
Description: MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Doppler ultrasound procedure
Description: The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound procedure
Description: The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doppler ultrasound procedure
Description: The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
Study: NCT05380388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine
Description: blood stage Plasmodium vivax malaria vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBV vaccine
Description: HBV Vaccine
Study: NCT05851456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT05054283

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflamatory biomarkers
Description: laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflamatory biomarkers
Description: laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
Study: NCT05854121

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional Electrical Stimulation
Description: Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Constrained Induced Movement Therapy
Description: Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
Study: NCT05549336

Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
Study: NCT05579145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Second Expiratory Pause
Description: Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-Second Expiratory Pause
Description: Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
Study: NCT06151847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Resection
Description: Undergo tumor resection
Study: NCT05992662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Training Programme in Bariatric Surgey Patients
Description: ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~* Reminder of weekly practices~* Recording changes in mindful eating in participant experience diaries during the follow-up
Study: NCT05222009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Study: NCT04934241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
Study: NCT05285956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm app
Description: Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
Study: NCT05705336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Oral Product
Description: Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
Study: NCT04924088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical-legal partnership
Description: Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to pro-bono lawyer
Description: Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
Study: NCT05501847

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Patient with no ventricular hypertrophy
Description: Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype.
Study: NCT06480370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISIS IOM System
Description: Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
Study: NCT05142072

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D3
Description: intranasal film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: intranasal film
Study: NCT06584643

Intervention type: DIAGNOSTIC_TEST
Intervention: gasdermin d
Description: evaluation of serum gasdermin d in vitligo patients and healthy controls

Intervention type: DIAGNOSTIC_TEST
Intervention: gasdermin d
Description: evaluation of serum gasdermin d in vitligo patients and healthy controls
Study: NCT05290857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restart DOAC within 7 days of clinical hemostasis after GI bleeding
Description: In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
Description: In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team.
Study: NCT05341063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Education
Description: Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
Study: NCT04933838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: atelocollagen
Description: This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: atelocollagen
Description: This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL).
Study: NCT04715503

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging, 18F-FDG
Description: PET-MRI with 18F-FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging, 68Ga-DOTANOC
Description: PET-CT with 68Ga-DOTANOC
Study: NCT06456307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)
Description: The intervention includes systematic screening for PMAD symptoms using PHQ-2 and GAD-2, non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) and in-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to PM+
Study: NCT05767723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Description: Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy: Ticagrelor alone OR Prasugrel alone
Description: Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
Study: NCT05593510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No prep ready-to-eat meals
Description: Pantry clients will select no prep ready-to-eat meals for up to 14-days' worth of meals for themselves and 2-members of their household using an online food selection platform. The food retailer supplying the meals produces over 70 meals. We have elected to study 14-days of meals to offer clients variety and determine which flavors are most desirable to clients. After ordering, meals will be retrieved from a refrigeration unit, boxed by pantry staff, and brought to the participant to take home. An example dinner is Teriyaki Chicken with Roasted Potatoes and Broccoli, and an example breakfast is Omelet with Peppers and Zucchini. Meals can be stored in a refrigerator or freezer and eaten immediately or after reheating depending on the meal and consumer preference.
Study: NCT05604326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways Intervention
Description: Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers (in English or Spanish) in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual in English or Spanish, depending on the family's home language. Sessions will review information about autism, interactional strategies, and Applied Behavioral Analysis (ABA) techniques from the program manual, demonstrate intervention strategies, and provide caregivers with practice feedback and self-reflection.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education Intervention (PEI)
Description: Caregivers will access a 20-30-minute video lesson and associated handouts (in English or Spanish, depending on the parent's home language) every other week for 24 weeks. On the off week, the caregiver will meet with a trained clinician (in English or Spanish) for 30 minutes without the child. Lessons will cover autism, social attention delays, evidence-based interventions, self-regulation, talking with your child, playing with your child, principles of managing behavior, knowing your rights, and self-care. The first and last visit will occur in the family's home or another convenient location. All other visits will take place over Zoom videoconferencing software.
Study: NCT05593510

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ingredient bundles (e.g. meal kits)
Description: Ingredient bundles will group individual meal ingredients (e.g., chicken, teriyaki, broccoli, potatoes) in a bag or box and pair those healthy food items with a recipe that instructs the client on how to make a healthier meal. Similar to the no prep ready-to-eat meal initiative, clients will select ingredient bundles for themselves and 2-members of their household using the food pantry online food selection platform. The ingredient bundles will closely replicate the no prep ready-to-eat meals.
Study: NCT04705402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
Study: NCT05376787

Intervention type: DEVICE
Intervention: Medline NE Grounding Pad
Description: Split Universal Grounding Pads
Study: NCT04845087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozonized water
Description: Irrigation of dental implants with ozonized water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Irrigation of dental implants with water
Study: NCT03824145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: The attention control participants will receive a home/work organization intervention:
Study: NCT06477757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Extracorporeal Circulation
Description: Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Extracorporeal Circulation
Description: Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
Study: NCT05414201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous Injection